10.1371/journal.pone.0056820.g005 Hiroaki Asai Hiroaki Asai Hiroshi Fujiwara Hiroshi Fujiwara Jun An Jun An Toshiki Ochi Toshiki Ochi Yukihiro Miyazaki Yukihiro Miyazaki Kozo Nagai Kozo Nagai Sachiko Okamoto Sachiko Okamoto Junichi Mineno Junichi Mineno Kiyotaka Kuzushima Kiyotaka Kuzushima Hiroshi Shiku Hiroshi Shiku Hirofumi Inoue Hirofumi Inoue Masaki Yasukawa Masaki Yasukawa In vivo anti-lung cancer activity mediated by double-transfected effector cells in therapeutic xenografted mouse models. Public Library of Science 2013 vivo anti-lung cancer mediated double-transfected effector cells therapeutic xenografted 2013-02-19 15:15:58 Figure https://plos.figshare.com/articles/figure/_In_vivo_anti_lung_cancer_activity_mediated_by_double_transfected_effector_cells_in_therapeutic_xenografted_mouse_models_/158047 <p>(A) The amount of CCL2 produced by <i>luciferase</i>-transfected LK79 cells (LK79/luc) was similar to that produced by the parent LK79 cells. (B) Nine-week-old NOG mice (nā€Š=ā€Š18) inoculated into the abdominal wall with 5Ɨ10<sup>6</sup> LK79/luc cells were divided into 3 cohorts. On day 4, when each tumor mass had become palpable, three mice in each cohort started to receive weekly intravenous administration of 5Ɨ10<sup>6</sup> double-transfected effector cells (cohort iii; black circles), WT1-si<i>TCR</i> single-transfected effector cells (cohort ii; gray square), or CD8<sup>+</sup> T cells simply activated using OKT-3/IL-2 as a negative control (cohort i; clear circles), the effector cells all being generated from an identical donor. Intravenous administration was performed three times in total, and the relative mass burden was serially monitored on the basis of luciferase photon counts relative to those on day 4, before the start of therapeutic infusion. Double-transfected effector cells in cohort iii mice most effectively suppressed the growth of LK79/luc cells, notably in the immediate phase after therapeutic infusion (on day 7). In contrast, WT1-si<i>TCR</i> single-transfected effector cells gradually suppressed the growth of LK79/luc cells, being apparently dependent on time and the total number of effector cells infused. Effector cells that had been simply activated also displayed a marginal degree of tumor suppression, probably because of xenoreactivity. Error bars represent SDs. NGM-CD8<sup>+</sup> T cells indicate CD8<sup>+</sup> T cells simply activated using OKT-3/IL-2, expressing neither CCR2 nor WT1-specific TCR. (C) Serial bioluminescence images of mice in each cohort are shown. On day 28, 10 days after the last therapeutic infusion, durable growth suppression of LK79/luc cells was most evident in cohort iii mice that had received double-transfected effector cells. NGM-CD8<sup>+</sup> T cells represent CD8<sup>+</sup> T cells simply activated using OKT-3/IL-2, expressing neither CCR2 nor WT1-specific TCR.</p>